1. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Issue 10 (October 2021) Authors: Mercuri, Eugenio; Muntoni, Francesco; Baranello, Giovanni; Masson, Riccardo; Boespflug-Tanguy, Odile; Bruno, Claudio; Corti, Stefania; Daron, Aurore; Deconinck, Nicolas; Servais, Laurent; Straub, Volker; Ouyang, Haojun; Chand, Deepa; Tauscher-Wisniewski, Sitra; Mendonca, Nuno; Lavrov, Arseniy; Se... Journal: Lancet neurology Issue: Volume 20:Issue 10(2021) Page Start: 832 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗